Treatment of patients with aortic atherosclerotic disease with paclitaxel-associated lipid nanoparticles
Carregando...
Citações na Scopus
36
Tipo de produção
article
Data de publicação
2016
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
SENRA, Tiago
PALADINO-FILHO, Antonio T.
PINTO, Ibraim M. F.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
CLINICS, v.71, n.8, p.435-439, 2016
Resumo
OBJECTIVE: The toxicity of anti-cancer chemotherapeutic agents can be reduced by associating these compounds, such as the anti-proliferative agent paclitaxel, with a cholesterol-rich nanoemulsion (LDE) that mimics the lipid composition of low-density lipoprotein (LDL). When injected into circulation, the LDE concentrates the carried drugs in neoplastic tissues and atherosclerotic lesions. In rabbits, atherosclerotic lesion size was reduced by 65% following LDE-paclitaxel treatment. The current study aimed to test the effectiveness of LDE-paclitaxel on inpatients with aortic atherosclerosis. METHODS: This study tested a 175 mg/m(2) body surface area dose of LDE-paclitaxel (intravenous administration, 3/3 weeks for 6 cycles) in patients with aortic atherosclerosis who were aged between 69 and 86 yrs. A control group of 9 untreated patients with aortic atherosclerosis (72-83 yrs) was also observed. RESULTS: The LDE-paclitaxel treatment elicited no important clinical or laboratory toxicities. Images were acquired via multiple detector computer tomography angiography (64-slice scanner) before treatment and at 1-2 months after treatment. The images showed that the mean plaque volume in the aortic artery wall was reduced in 4 of the 8 patients, while in 3 patients it remained unchanged and in one patient it increased. In the control group, images were acquired twice with an interval of 6-8 months. None of the patients in this group exhibited a reduction in plaque volume; in contrast, the plaque volume increased in three patients and remained stable in four patients. During the study period, one death unrelated to the treatment occurred in the LDE-paclitaxel group and one death occurred in the control group. CONCLUSION: Treatment with LDE-paclitaxel was tolerated by patients with cardiovascular disease and showed the potential to reduce atherosclerotic lesion size.
Palavras-chave
Nanoparticles, Solid Lipid Particles, Taxanes, Cardiovascular Disease Treatment, LDL Receptors, Drug Targeting
Referências
- Bulgarelli A, 2012, J CARDIOVASC PHARM, V59, P308, DOI 10.1097/FJC.0b013e318241c385
- Capmany Ramon Pujadas, 2010, Curr Cardiol Rev, V6, P184, DOI 10.2174/157340310791658712
- Carvalho PO, 2014, J THORAC CARDIOV SUR, V148, P1765, DOI 10.1016/j.jtcvs.2014.05.026
- Contente TC, 2014, J PHARM PHARMACOL, V66, P1698, DOI 10.1111/jphp.12296
- DELALLERAMOYA M, 1992, ARTERIOSCLER THROMB, V12, P1363
- Fujita S, 2013, CLIN CARDIOL, V36, P352, DOI 10.1002/clc.22121
- Geraci A, 2000, NEUROLOGY, V54, P749
- HO YK, 1978, BLOOD, V52, P1099
- Lima ES, 2004, CLIN CHEM, V50, P1086, DOI 10.1373/clinchem.2004.032383
- Lourenco DD, 2011, J THORAC CARDIOV SUR, V141, P1522, DOI 10.1016/j.jtcvs.2010.08.032
- Maranhao RC, 2008, ATHEROSCLEROSIS, V197, P959, DOI 10.1016/j.atherosclerosis.2007.12.051
- MARANHAO RC, 1994, CANCER RES, V54, P4660
- MARANHAO RC, 1993, LIPIDS, V28, P691, DOI 10.1007/BF02535988
- Margolis J, 2007, CLIN CARDIOL, V30, P165, DOI 10.1002/clc.20066
- Montgomery DH, 1996, J AM COLL CARDIOL, V27, P95, DOI 10.1016/0735-1097(95)00431-9
- Pires L, 2009, CANCER CHEMOTH PHARM, V63, P281, DOI 10.1007/s00280-008-0738-2
- Rodrigues DG, 2002, J PHARM PHARMACOL, V54, P765, DOI 10.1211/0022357021779104
- ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004
- ROWINSKY EK, 1990, J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247
- Sen S, 2002, STROKE, V33, P930, DOI 10.1161/01.STR.0000014210.99337.D7
- Tavares ER, 2011, INT J NANOMED, V6, P2297, DOI 10.2147/IJN.S24048
- Ueno Y, 2015, ATHEROSCLEROSIS, V239, P476, DOI 10.1016/j.atherosclerosis.2015.02.021